Atara Biotherapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference
Aug 02, 2017 12:00 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for patients with cancer and multiple sclerosis...
Momenta Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
Aug 02, 2017 12:00 pm UTC| Business
$10M milestone payment from Sandoz earned for the second anniversary of Glatopa® 20 mg as the sole FDA-approved generic on the market for patients with relapsing forms of multiple sclerosis Ended second quarter with a...
Seaspan partners with DNV GL for EU-MRV Verification
Aug 02, 2017 12:00 pm UTC| Business
Houston, Texas, Aug. 02, 2017 -- EU-MRV regulation aims to quantify and reduce CO2 emissions from shipping while creating a new method for benchmarking. Due to the global nature of the maritime business, most vessels...
R1 RCM Appoints Gary Long as Chief Commercial Officer
Aug 02, 2017 12:00 pm UTC| Business
CHICAGO, Aug. 02, 2017 -- R1 RCM Inc. (NASDAQ:RCM), a leading provider of revenue cycle management and physician advisory services to healthcare providers, today announced the appointment of Gary Long to the newly...
Cognition Therapeutics Elects Lazard Vice Chairman Stephen Sands to Board of Directors
Aug 02, 2017 12:00 pm UTC| Business
Pittsburgh, Aug. 02, 2017 -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive...
ConnectWise Wins Four Gold, Two Silver 2017 Readers' Choice Awards
Aug 02, 2017 12:00 pm UTC| Business
TAMPA, Fla., Aug. 02, 2017 -- More than 500 ChannelPro-SMB readers cast their votes and selected ConnectWise®, a company that transforms how technology solution providers successfully build, manage and grow their...
Aug 02, 2017 12:00 pm UTC| Business
LAWRENCEVILLE, N.J., Aug. 02, 2017 -- Celsion Corporation (NASDAQ:CLSN) today announced findings from the translational research data from its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1,...